Farabursen

N/A

Report date: 2025/02/26 11:41:51
NME

Base Information

Drug NameFarabursen
Drug Alias NameRGLS-8429RGLS8429
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionMicroRNA-17 inhibitors
TargetsMicroRNA-17
Therapy Area/IndicationsPolycystic Kidney, Autosomal Dominant
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesRegulus Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesRegulus Therapeutics IncRegulus Therapeutics
Inactive CompaniesN/A
Active IndicationsPolycystic Kidney, Autosomal Dominant
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A